# Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

> **NCT02636725** · PHASE2 · COMPLETED · sponsor: **Jonathan Trent, MD, PhD** · enrollment: 33 (actual)

## Conditions studied

- Alveolar Soft Part Sarcoma
- Soft Tissue Sarcomas

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02636725
- **Lead sponsor:** Jonathan Trent, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-19
- **Primary completion:** 2018-05-08
- **Final completion:** 2023-03-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636725, "Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02636725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*